News | May 10, 2024
Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
The product is used to treat amyotrophic lateral sclerosis
The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
With this, for all our USFDA facilities, EIRs are in place
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Subscribe To Our Newsletter & Stay Updated
